Disease relevance of LIDAMIDINE

• Clonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer [1].
• Lidamidine was found to have no significant effect on frequency and severity of abdominal pain or abdominal bloating [2].
• A randomised double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome [3].
• Amplitude of induced rectoanal inhibitory reflex decreased after lidamidine (24.6 +/- 2.9 vs 17.3 +/- 3 mmHg; p = 0.02) [3].

High impact information on LIDAMIDINE

• In summary, lidamidine significantly delayed gastric emptying but had no significant effect on small bowel transit [4].
• WHR 1049, a potent metabolite of lidamidine, has antidiarrheal and antimotility effects on the small intestine in rats [5].
• Lidamidine HCl has been suggested to be effective in treating certain motor disorders of the gastrointestinal tract [5].
• Prevention of guanine nucleotide-induced reductions in muscarinic agonist binding to rabbit ileal submucosal membranes by lidamidine and tetracaine [6].
• Lidamidine is a clinically effective antidiarrheal agent that inhibits intestinal secretion, reduces intestinal transit, and inhibits smooth muscle contraction [7].

Anatomical context of LIDAMIDINE

• Thin-layer chromatography of subcellular fraction extracts revealed different distribution patterns for lidamidine and metabolites in each fraction [8].
• Effect of lidamidine, a proposed alpha 2-adrenoreceptor agonist, on salt and water transport in human jejunum [9].
• These results indicate that the hyperglycemic effect of lidamidine is primarily due to the activation of peripherally located alpha 2-adrenoceptors that inhibit the release of insulin from pancreatic beta-cells [10].
• Increasing Ca2+ concentrations in the bathing medium from 0.9 mmol/l to 7.2 mmol/l effectively antagonized the lidamidine inhibition of responses to BaCl2 and acetylcholine in the gravid rat uterus preparation [11].

Associations of LIDAMIDINE with other chemical compounds

• Experiments were performed to investigate the effect of two alpha 2-adrenoreceptor agonists, clonidine and lidamidine, and a specific alpha 2-adrenoreceptor antagonist, idazoxan, on gastric emptying and mouth to caecum transit time (MCTT) of a radiolabelled meal in 27 healthy male subjects [12].
• Effect of lidamidine on transepithelial potential difference evoked by prostaglandin E2 in human jejunum [13].
• Therefore, the effects of loperamide and lidamidine on contractile and myoelectrical activity were studied in strips of the circular muscle of the cat colon in vitro [14].

Analytical, diagnostic and therapeutic context of LIDAMIDINE

• The effects of a new antidiarrheal agent, lidamidine (10 mg per os) and an identical placebo on jejunal fluid and electrolyte transport in vivo were investigated in five normal volunteers during steady-state perfusion of a 25-cm length of jejunum with a plasma-like solution [9].
• Rectal painful sensation decreased after treatment with lidamidine (54.8 +/- 5.4 vs 43.6 +/- 3.5 ml; p < 0.05) as well as with placebo (p < 0.05) [3].
• The hyperglycemic response was evident 10 min after oral administration of lidamidine and lasted for 4 hr [10].

References